Allo HSCT Using RIC and PTCy for Hematological Diseases
Public ClinicalTrials.gov record NCT05805605. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Study identification
- NCT ID
- NCT05805605
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- 56 participants
Conditions and interventions
Conditions
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Biphenotypic Acute Leukemia
- Burkitt Lymphoma
- Chronic Myelogenous Leukemia
- Follicular Lymphoma
- Leukemia, Myeloid
- Marginal Zone Lymphoma
- Myelodysplastic Syndrome With Excess Blasts-1
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Neoplasm
- Plasma Cell Leukemia
- Prolymphocytic Leukemia
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed T-Cell Lymphoma
- Small Lymphocytic Lymphoma
- Undifferentiated Leukemia
Interventions
- Allopurinol 300 MG Drug
- Bone Marrow Cell Transplant Biological
- Cyclophosphamide Drug
- Fludarabine Drug
- Mycophenolate Mofetil Drug
- Peripheral Blood Stem Cell Transplant Biological
- Sirolimus Pill Drug
- Total Body Irradiation Radiation
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2023
- Primary completion
- Oct 21, 2027
- Completion
- Oct 21, 2028
- Last update posted
- Jun 30, 2025
2023 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05805605, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05805605 live on ClinicalTrials.gov.